DelveInsight’s “Thyroid Eye Disease Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock key insights into the Thyroid Eye Disease Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Thyroid Eye Disease Therapeutics Market Outlook

Key Takeaways from the Thyroid Eye Disease Market Report

• In April 2025, Tourmaline Bio Inc. announced a study of Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
• In April 2025, Viridian Therapeutics Inc. conducted a study are to determine if VRDN-003 is efficacious, safe and tolerable when administered as subcutaneous/SC injections every 4 weeks or every 8 weeks compared to placebo in participants with chronic TED.
• In April 2025, Amgen organized a study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
• The total prevalent cases of thyroid eye disease in the United States were around 1,012,000 cases in 2022.
• The US contributed to the largest prevalent population of thyroid eye disease, acquiring ~42% of the 7MM in 2022. Whereas Germany accounted for around 13% and Japan accounted for around 8% of the total population share, respectively, in 2022.
• Among EU4 countries, Germany accounted for the largest number of thyroid eye disease cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
• According to DelveInsight estimates, there were around 16,300 cases of acute Thyroid Eye Disease and 41,900 cases of chronic Thyroid Eye Disease in Japan in 2022. These cases are projected to increase during the forecasted period.
• In the 7MM, approximately 20% of the patient share is attributed to males, whereas only 80% of females suffer from thyroid eye disease.
• The diagnosis and treatment rate of thyroid eye disease is expected to increase in the coming years due to the increase in expected approvals of several pipeline candidates for the treatment of thyroid eye disease, thus leading to the increase in awareness among patients and clinicians.
• The leading Thyroid Eye Disease Companies such as Allergan PLC, Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., Astellas Pharma Inc., Olympus Medical, Butterfly Medical, SRS Medical, Teleflex Interventional Urology, Urotronic, Zenflow, ProArc Medical, Medion Biodesign, and others.
• Promising Thyroid Eye Disease Pipeline Therapies such as RVT-1401, VRDN-003, Batoclimab, Veligrotug (VRDN-001), Teprotumumab, IBI311 and others.

Stay ahead in the competitive landscape of the Thyroid Eye Disease Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Thyroid Eye Disease Treatment Market Size

Thyroid Eye Disease Epidemiology Segmentation in the 7MM

• Thyroid Eye Disease Prevalent Cases
• Thyroid Eye Disease Diagnosed Prevalent Cases
• Thyroid Eye Disease Gender-specific Diagnosed Prevalent Cases
• Thyroid Eye Disease Diagnosed Prevalent Cases
• Moderate-to-severe Drug-treated Cases of Acute Thyroid Eye Disease Cases

Download the report to understand which factors are driving Thyroid Eye Disease epidemiology trends @ Thyroid Eye Disease Prevalence

Thyroid Eye Disease Marketed drugs

• TEPEZZA (teprotumumab): Horizon Therapeutics

Insulin-like growth factor I receptor (IGF-IR) is implicated as a potential cause of thyroid eye disease, and overexpression of IGF-IR is found in orbital fibroblasts and lymphocytes. Features of thyroid eye disease include periorbital edema, proptosis, strabismus, and eyelid retraction, which can progress to vision-threatening complications, such as exposure keratopathy and compression neuropathy. Current management of this condition is not very effective and includes systemic steroids or radiation of the orbit, both of which are associated with significant adverse effects and complications.

Thyroid Eye Disease Emerging drugs

• Batoclimab: Immunovant Sciences

Immunovant’s first investigational product, batoclimab (IMVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). In nonclinical studies and clinical trials, batoclimab has been observed to reduce IgG antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases, and, as a result, this product candidate has the potential to address a variety of IgG-mediated autoimmune diseases as a self-administered SC injection.

To learn more about Thyroid Eye Disease Treatment guidelines, visit @ Thyroid Eye Disease Market Drivers and Barriers

Thyroid Eye Disease Treatment Market Landscape

Thyroid eye disease treatment has evolved from nonspecific immunosuppression to targeted biological therapies. Current medical therapies target the active stage to decrease inflammation, minimize the worsening of functional ocular sequel, and in some cases, improve ocular signs, including proptosis and double vision. The mainstay of treatment for years has been steroids and orbital radiation (ORT). Several biologics have been assessed in recent years: rituximab, tocilizumab, and teprotumumab.

Thyroid Eye Disease Market Outlook

Thyroid Eye Disease treatment in the US is entering a new era with changing dynamics. To this date, only one drug has been approved by the US FDA to treat Thyroid Eye Disease: insulin-like growth factor-I receptor antagonist TEPEZZA. It is worth mentioning that the European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines 2021 recommends IV methylprednisolone in combination with oral mycophenolate sodium (or mofetil) as the first-line treatment for moderate-to-severe and acute thyroid eye disease, and in the more severe forms of moderate-to-severe and acute thyroid eye disease, including constant/inconstant diplopia, severe inflammatory signs and exophthalmos >25 mm, IV methyl-prednisolone at the highest cumulative dose (7.5 g per cycle) as monotherapy represents an additional valid first-line treatment.

Explore the dynamics of the Thyroid Eye Disease Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Thyroid Eye Disease Ongoing Clinical Trials Analysis

Scope of the Thyroid Eye Disease Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Thyroid Eye Disease Companies- Allergan PLC, Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., Astellas Pharma Inc., Olympus Medical, Butterfly Medical, SRS Medical, Teleflex Interventional Urology, Urotronic, Zenflow, ProArc Medical, Medion Biodesign, and others.
• Thyroid Eye Disease Pipeline Therapies- RVT-1401, VRDN-003, Batoclimab, Veligrotug (VRDN-001), Teprotumumab, IBI311 and others.
• Thyroid Eye Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Thyroid Eye Disease Unmet Needs, KOL’s views, Analyst’s views, Thyroid Eye Disease Market Access and Reimbursement

Table of Content

1 Key Insights

2 Thyroid Eye Disease Market Report Introduction

3 Thyroid Eye Disease Market Overview at a Glance

4 Executive Summary of Thyroid Eye Disease

5 Epidemiology and Market Methodology

6 Disease Background and Overview

7 Thyroid Eye Disease Epidemiology and Patient Population

8 Thyroid Eye Disease Patient Journey

9 Key Endpoints in Thyroid Eye Disease Clinical Trials

10 Thyroid Eye Disease Marketed Therapies

11 Thyroid Eye Disease Emerging Therapies

12 Thyroid Eye Disease: The 7MM Analysis

13 Thyroid Eye Disease Market Access and Reimbursement

14 Thyroid Eye Disease KOL Views

15 Thyroid Eye Disease SWOT Analysis

16 Thyroid Eye Disease Unmet Needs

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/thyroid-eye-disease-market